Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

279 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Ruxolitinib for Glucocorticoid-Refractory Chronic Graft-versus-Host Disease.
Zeiser R, Polverelli N, Ram R, Hashmi SK, Chakraverty R, Middeke JM, Musso M, Giebel S, Uzay A, Langmuir P, Hollaender N, Gowda M, Stefanelli T, Lee SJ, Teshima T, Locatelli F; REACH3 Investigators. Zeiser R, et al. Among authors: giebel s. N Engl J Med. 2021 Jul 15;385(3):228-238. doi: 10.1056/NEJMoa2033122. N Engl J Med. 2021. PMID: 34260836 Clinical Trial.
Molnupiravir is effective in patients with haematological malignancies.
Bołkun Ł, Pula B, Kołkowska-Leśniak A, Morawska M, Cichocka E, Charlinski G, Garus B, Giebel S, Piszcz J, Drozd-Sokolowska J, Kwiatkowski J, Biernat M, Hus I, Lech-Maranda E, Długosz-Danecka M, Giannopoulos K, Wróbel T. Bołkun Ł, et al. Among authors: giebel s. Int J Cancer. 2023 Sep 15;153(6):1251-1256. doi: 10.1002/ijc.34442. Epub 2023 Feb 7. Int J Cancer. 2023. PMID: 36691818
Correction: Non-T-depleted haploidentical transplantation with post-transplant cyclophosphamide in patients with secondary versus de novo AML in first complete remission: a study from the ALWP/EBMT.
Nagler A, Labopin M, Blaise D, Raiola AM, Corral LL, Bramanti S, Sica S, Kwon M, Koc Y, Pavlu J, Kulagin A, Busca A, Rodríguez AB, Reményi P, Schmid C, Brissot E, Sanz J, Bazarbachi A, Giebel S, Ciceri F, Mohty M. Nagler A, et al. Among authors: giebel s. J Hematol Oncol. 2023 Sep 29;16(1):106. doi: 10.1186/s13045-023-01501-w. J Hematol Oncol. 2023. PMID: 37775766 Free PMC article. No abstract available.
Are syngeneic donors a viable donor option in allogeneic haematopoietic cell transplantation for MDS? A brief report on behalf of the Chronic Malignancies Working Party of the EBMT and review of current literature.
Robin M, Gras L, Koster L, Saccardi R, Finke J, Forcade E, Rovira M, Kobbe G, Reményi P, Apperley J, Smaranda A, Bay JO, Casper J, de Wreede LC, Giebel S, Grillo G, Heras I, Potter V, Tischer J, Trociukas I, Nachbaur D, Drozd-Sokolowska J, Raj K, Gurnari C, Yakoub-Agha I, Onida F, Scheid C, McLornan D. Robin M, et al. Among authors: giebel s. Bone Marrow Transplant. 2023 Aug;58(8):942-945. doi: 10.1038/s41409-023-01991-9. Epub 2023 Apr 25. Bone Marrow Transplant. 2023. PMID: 37185613 No abstract available.
Efficacy, quality of life, and safety of methotrexate versus interferon in head-to-head treatment in advanced stages of mycosis fungoides and Sezary syndrome. Prospective trial (NCT02323659).
Chmielowska E, Sokołowska-Wojdyło M, Olszewska B, Studziński M, Grzanka-Gadzińska A, Zabłotna M, Olek-Hrab K, Iwanowski T, Olejniczak M, Krause A, Giebel S. Chmielowska E, et al. Among authors: giebel s. Postepy Dermatol Alergol. 2021 Apr;38(2):295-301. doi: 10.5114/ada.2021.106206. Epub 2021 May 22. Postepy Dermatol Alergol. 2021. PMID: 36751548 Free PMC article.
MICB Genetic Variants and Its Protein Soluble Level Are Associated with the Risk of Chronic GvHD and CMV Infection after Allogeneic HSCT.
Siemaszko J, Dratwa M, Szeremet A, Majcherek M, Czyż A, Sobczyk-Kruszelnicka M, Fidyk W, Solarska I, Nasiłowska-Adamska B, Skowrońska P, Bieniaszewska M, Tomaszewska A, Basak GW, Giebel S, Wróbel T, Bogunia-Kubik K. Siemaszko J, et al. Among authors: giebel s. Arch Immunol Ther Exp (Warsz). 2024 Jun 7;72(1). doi: 10.2478/aite-2024-0012. eCollection 2024 Jan 1. Arch Immunol Ther Exp (Warsz). 2024. PMID: 38847554 Free article.
Prognostic factors impacting post-transplant outcomes in adult T-cell acute lymphoblastic leukemia: a registry-based study by the EBMT acute leukemia working party.
El Cheikh J, Ngoya M, Galimard JE, Reményi P, Kulagin A, Aljurf M, Mousavi A, Wu D, Ozcelik T, Salmenniemi U, Castilla-Llorente C, Socie G, Helbig G, Schroeder T, Sakellari I, Rambaldi A, Burt R, Busca A, Balsat M, Stelljes M, Brissot E, Giebel S, Peric Z, Nagler A, Bazarbachi A, Ciceri F, Mohty M. El Cheikh J, et al. Among authors: giebel s. Bone Marrow Transplant. 2024 Jun 4. doi: 10.1038/s41409-024-02300-8. Online ahead of print. Bone Marrow Transplant. 2024. PMID: 38834689
PTCy versus CNI-based GVHD prophylaxis in HLA-matched transplants for Hodgkin Lymphoma: a study of the LWP of the EBMT.
Montoro J, Ngoya M, Kulagin A, Giebel S, Broers AEC, Bramanti S, Halahleh K, Perez-Simon JA, Solano C, Ozcelik T, Blaise D, Sanz J, Henriques M, Peffault de Latour R, Martino R, Scheid C, Fox L, Gromek T, Jurado M, Sakellari I, van Gorkom G, Matteucci P, Nagler A, Koc Y, Glass B. Montoro J, et al. Among authors: giebel s. Blood Adv. 2024 May 29:bloodadvances.2024013328. doi: 10.1182/bloodadvances.2024013328. Online ahead of print. Blood Adv. 2024. PMID: 38810260
279 results